Venetoclax resistance mechanisms are not limited to alterations only in BCL2, as acquired mutations in pro-apoptotic BAX have been identified in mantle cell lymphoma [36], CLL [39], and AML [38], but none of our acquired venetoclax-resistant DLBCL lines generated a BAX mutation. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.